405 related articles for article (PubMed ID: 19706626)
1. A trade agreement's impact on access to generic drugs.
Shaffer ER; Brenner JE
Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
[TBL] [Abstract][Full Text] [Related]
2. CAFTA will harm HIV care, according to critics. Final agreement helps drug companies, they say.
AIDS Alert; 2004 Feb; 19(2):17-8. PubMed ID: 15011625
[TBL] [Abstract][Full Text] [Related]
3. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
4. Trade agreements, intellectual property, and the role of the World Bank in improving access to medicines in developing countries.
Rovira J
Yale J Health Policy Law Ethics; 2004; 4(2):401-13. PubMed ID: 15536921
[No Abstract] [Full Text] [Related]
5. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
6. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
7. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
8. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
9. A study of pharmaceutical data exclusivity laws in Latin America: is access to affordable medicine threatened?
Cartagena RG; Attaran A
Health Law J; 2009; 17():269-96. PubMed ID: 20608321
[No Abstract] [Full Text] [Related]
10. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
Zain S
Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
[No Abstract] [Full Text] [Related]
11. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
12. The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules.
Scott Morton F
Rand J Econ; 1997; 28(2):269-90. PubMed ID: 11794358
[TBL] [Abstract][Full Text] [Related]
13. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
14. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
Kong Y
Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
[TBL] [Abstract][Full Text] [Related]
15. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
16. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
17. Effect of generic drug competition on the price of prescription drugs in Ontario.
Lexchin J
CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
[TBL] [Abstract][Full Text] [Related]
18. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
19. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
Roehr B
BMJ; 2012 Dec; 345():e8464. PubMed ID: 23236054
[No Abstract] [Full Text] [Related]
20. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
